相关参考文献
注意:仅列出部分参考文献,下载原文获取全部文献信息。Sotagliflozin in Patients with Diabetes and Recent Worsening Heart Failure
Deepak L. Bhatt et al.
NEW ENGLAND JOURNAL OF MEDICINE (2021)
Looking deeper into the findings of DARE-19: Failure or an open door to future success?
Theocharis Koufakis et al.
PHARMACOLOGICAL RESEARCH (2021)
Sodium-glucose cotransporter 2 inhibitors (SGLT2i) and cardiac arrhythmias: a systematic review and meta-analysis
Hang-Long Li et al.
CARDIOVASCULAR DIABETOLOGY (2021)
Cardiac Late Sodium Channel Current Is a Molecular Target for the Sodium/Glucose Cotransporter 2 Inhibitor Empagliflozin
Koenraad Philippaert et al.
CIRCULATION (2021)
Epidemiology, Pathophysiology, Diagnosis and Treatment of Heart Failure in Diabetes
Jin Joo Park
DIABETES & METABOLISM JOURNAL (2021)
Insights Into the Results of Sotagliflozin Cardiovascular Outcome Trials: Is Dual Inhibition the Cherry on the Cake of Cardiorenal Protection?
Theocharis Koufakis et al.
DRUGS (2021)
Effect of dapagliflozin on ventricular arrhythmias, resuscitated cardiac arrest, or sudden death in DAPA-HF
James P. Curtain et al.
EUROPEAN HEART JOURNAL (2021)
Anti-arrhythmic and inotropic effects of empagliflozin following myocardial ischemia
Mohammed Ali Azam et al.
LIFE SCIENCES (2021)
Off-target effects of sodium-glucose co-transporter 2 blockers: empagliflozin does not inhibit Na+/H+ exchanger-1 or lower [Na+]i in the heart
Yu Jin Chung et al.
CARDIOVASCULAR RESEARCH (2021)
Empagliflozin Blunts Worsening Cardiac Dysfunction Associated With Reduced NLRP3 (Nucleotide-Binding Domain-Like Receptor Protein 3) Inflammasome Activation in Heart Failure
Nikole J. Byrne et al.
CIRCULATION-HEART FAILURE (2020)
The use of sodium-glucose co-transporter 2 inhibitors in the inpatient setting: Is the risk worth taking?
Theocharis Koufakis et al.
JOURNAL OF CLINICAL PHARMACY AND THERAPEUTICS (2020)
Effects of empagliflozin versus placebo on cardiac sympathetic activity in acute myocardial infarction patients with type 2 diabetes mellitus: the EMBODY trial
Wataru Shimizu et al.
CARDIOVASCULAR DIABETOLOGY (2020)
Interpreting the results of theVERTIS-CVtrial: Is this the end of the class effect perspective?
Theocharis Koufakis et al.
JOURNAL OF DIABETES (2020)
Acute canagliflozin treatment protects against in vivo myocardial ischemia-reperfusion injury in non-diabetic male rats and enhances endothelium-dependent vasorelaxation
Alex Ali Sayour et al.
JOURNAL OF TRANSLATIONAL MEDICINE (2019)
Dapagliflozin in Patients with Heart Failure and Reduced Ejection Fraction
J. J. V. McMurray et al.
NEW ENGLAND JOURNAL OF MEDICINE (2019)
SGLT1 inhibition: Pros and cons
Vasilis Tsimihodimos et al.
EUROPEAN JOURNAL OF PHARMACOLOGY (2018)
Class effects of SGLT2 inhibitors in mouse cardiomyocytes and hearts: inhibition of Na+/H+ exchanger, lowering of cytosolic Na+ and vasodilation
Laween Uthman et al.
DIABETOLOGIA (2018)
Declining Risk of Sudden Death in Heart Failure
Li Shen et al.
NEW ENGLAND JOURNAL OF MEDICINE (2017)
What causes sudden death in heart failure?
GF Tomaselli et al.
CIRCULATION RESEARCH (2004)